Literature DB >> 12937219

TNF-alpha renders human peritoneal mesothelial cells sensitive to anti-Fas antibody-induced apoptosis.

Jinn-Yang Chen1, Chin-Wen Chi, Hui-Ling Chen, Chiung-Pei Wan, Wu-Chang Yang, An-Hang Yang.   

Abstract

BACKGROUND: Fas-mediated apoptosis is important in the regulation of immune response. Human peritoneal mesothelial cells (HPMCs) are able to regulate peritoneal inflammation, but the role of Fas in HPMCs is not clear. This study addresses the mechanisms of Fas-mediated apoptosis in HPMCs.
METHODS: Tumour necrosis factor-alpha (TNF-alpha) primed HPMCs were stimulated with agonistic anti-Fas antibody. The expression of Fas was evaluated by real-time reverse transcription polymerase chain reaction (TaqMan quantitative polymerase chain reaction) and flow cytometry. Apoptosis was assessed by nuclear morphology, TUNEL assay, fractional DNA content and cytokeratin 18 cleavage. Caspase activation and bcl-2 expression were analysed by western blotting. The phagocytosis of apoptotic HPMCs was demonstrated by immunofluorescence and transmission electron microscopy.
RESULTS: Cultured HPMCs constitutively expressed Fas, and the Fas expression was upregulated by TNF-alpha. TNF-alpha primed HPMCs underwent apoptosis after anti-Fas antibody treatment, and the apoptotic HPMCs could be phagocytosed by macrophages. TNF-alpha was able to downregulate bcl-2 expression. Activation of caspase-3 and caspase-8 was noted during the apoptotic process. The inhibitors of either caspase-3 or caspase-8 could prevent the Fas-induced apoptosis in HPMCs. We also detected increased HPMC apoptosis in dialysate effluent during the recovery phase of peritonitis in peritoneal dialysis patients.
CONCLUSIONS: TNF-alpha directs HPMCs to commit apoptosis via the Fas/Fas ligand pathway through a modulation of Fas and bcl-2. Our study shows that HPMCs undergo apoptosis during peritonitis and suggests that the apoptosis of HPMCs may be related to the resolution of peritoneal inflammation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12937219     DOI: 10.1093/ndt/gfg275

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Destruction of gastric cancer cells to mesothelial cells by apoptosis in the early peritoneal metastasis.

Authors:  Di Na; Funan Liu; Zhifeng Miao; Zongmin Du; Huimian Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

Review 2.  Biomarkers of obesity and subsequent cardiovascular events.

Authors:  Salma Musaad; Erin N Haynes
Journal:  Epidemiol Rev       Date:  2007-05-10       Impact factor: 6.222

3.  Astragalus extract inhibits destruction of gastric cancer cells to mesothelial cells by anti-apoptosis.

Authors:  Di Na; Fu-Nan Liu; Zhi-Feng Miao; Zong-Min Du; Hui-Mian Xu
Journal:  World J Gastroenterol       Date:  2009-02-07       Impact factor: 5.742

4.  Gastric cancer cell supernatant causes apoptosis and fibrosis in the peritoneal tissues and results in an environment favorable to peritoneal metastases, in vitro and in vivo.

Authors:  Di Na; Zhi-Dong Lv; Fu-Nan Liu; Yan Xu; Cheng-Gang Jiang; Zhe Sun; Zhi-Feng Miao; Feng Li; Hui-Mian Xu
Journal:  BMC Gastroenterol       Date:  2012-04-20       Impact factor: 3.067

5.  Recombinant GPI-anchored TIMP-1 stimulates growth and migration of peritoneal mesothelial cells.

Authors:  Roghieh Djafarzadeh; Matthias Sauter; Susan Notohamiprodjo; Elfriede Noessner; Pankaj Goyal; Wolfgang Siess; Markus Wörnle; Andrea Ribeiro; Susanne Himmelein; Thomas Sitter; Peter J Nelson
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

6.  A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury.

Authors:  Beatriz Santamaría; Alberto Benito-Martin; Alvaro Conrado Ucero; Luiz Stark Aroeira; Ana Reyero; María Jesús Vicent; Mar Orzáez; Angel Celdrán; Jaime Esteban; Rafael Selgas; Marta Ruíz-Ortega; Manuel López Cabrera; Jesús Egido; Enrique Pérez-Payá; Alberto Ortiz
Journal:  PLoS One       Date:  2009-08-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.